Publications

BMC cancer

Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).

01-07-2017

European journal of cancer (Oxford, England : 1990)

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

01-06-2017

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).

01-04-2017

European journal of cancer (Oxford, England : 1990)

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

01-03-2017

Proceedings of the National Academy of Sciences of the United States of America

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.

21-02-2017

Breast cancer research and treatment

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

01-02-2017

Cancer treatment reviews

(Very) Early technology assessment and translation of predictive biomarkers in breast cancer.

01-01-2017

Biomarker insights

Prognostic Value of MammaPrint^® in Invasive Lobular Breast Cancer.

17-12-2016

Breast (Edinburgh, Scotland)

Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute.

01-12-2016

Cancer

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.

01-10-2016

Breast (Edinburgh, Scotland)

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.

01-10-2016

Breast cancer research and treatment

Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

01-09-2016

International journal of cancer

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.

15-08-2016

The Lancet. Oncology

10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.

01-08-2016

Genetics in medicine : official journal of the American College of Medical Genetics

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.

01-07-2016

Cancer research

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

01-07-2016

Breast cancer research and treatment

The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

01-07-2016

Cancer informatics

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

28-06-2016

Trials

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.

21-06-2016

Oncotarget

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

07-06-2016

Nederlands tijdschrift voor geneeskunde

[Living with incurable cancer].

29-04-2016

Cell

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

07-04-2016

Breast cancer research and treatment

Equivalence of MammaPrint array types in clinical trials and diagnostics.

01-04-2016

Breast cancer research and treatment

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.

01-04-2016

Journal of proteome research

Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.

01-04-2016

Journal of neuro-oncology

Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.

01-04-2016

Oncotarget

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.

19-01-2016

Scientific reports

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

05-01-2016

Molecular oncology

4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.

01-01-2016

Molecular cancer therapeutics

High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.

01-01-2016

Cureus

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?

24-12-2015

Breast (Edinburgh, Scotland)

St. Gallen endocrine response classes predict recurrence rates over time.

01-12-2015

Genes, chromosomes & cancer

Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.

01-12-2015

Therapeutic drug monitoring

Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study.

01-12-2015

Nature reviews. Clinical oncology

Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?

01-10-2015

Molecular oncology

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

01-10-2015

BMC cancer

The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).

03-09-2015

BMC cancer

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.

14-08-2015

Clinical breast cancer

Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

01-08-2015

Breast cancer research and treatment

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

01-08-2015

Clinical pharmacokinetics

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

01-08-2015

Molecular oncology

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

01-08-2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer.

10-06-2015

Molecular oncology

Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

01-06-2015

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Molecular profiling is rather likely to be cost effective.

10-05-2015

Clinical cancer research : an official journal of the American Association for Cancer Research

Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy.

15-02-2015

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model Framework.

01-11-2014

European journal of cancer (Oxford, England : 1990)

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.

01-09-2014

International journal of cancer

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.

01-09-2014

PloS one

Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases.

02-08-2014

Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08).

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).

Trastuzumab in combination with weekly paclitaxel and carboplatin as neo-adjuvant treatment for HER2-positive breast cancer: The TRAIN-study.

Estrogen receptor α wields treatment-specific enhancers between morphologically similar endometrial tumors.

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.

(Very) Early technology assessment and translation of predictive biomarkers in breast cancer.

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.

Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute.

A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.

Erratum to: The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.

10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study.

Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.

Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care.

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

[Living with incurable cancer].

A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.

Equivalence of MammaPrint array types in clinical trials and diagnostics.

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.

Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera.

Response of symptomatic brain metastases from HER-2 overexpressing breast cancer with T-DM1.

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.

High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.

Ongoing Remission Nineteen Years after High-dose Chemotherapy for Oligometastatic Breast Cancer; What Can We Learn from this Patient?

St. Gallen endocrine response classes predict recurrence rates over time.

Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.

Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study.

Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?

BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.

The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.

Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure.

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Challenges in the Use of DNA Repair Deficiency As a Biomarker in Breast Cancer.

Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

Molecular profiling is rather likely to be cost effective.

Breast cancers with a BRCA1-like DNA copy number profile recur less often than expected after high-dose alkylating chemotherapy.

Microsimulation Model For The Assessment Of Personalized Cancer Care: The Mapcca Model Framework.

Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial.

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy.

Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases.

This site uses cookies

Prognostic Value of MammaPrint^® in Invasive Lobular Breast Cancer.